Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis.
To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00038922
|Study Director:||Medical Monitor, MD||Wyeth is now a wholly owned subsidiary of Pfizer|